Lopinavir/ritonavir

Developed for: congenital human immunodeficiency virus
Investigated by: Bamrasnaradura Infectious Diseases Institute · Buddhachinaraj Hospital · Chulalongkorn University · Nakornping Hospital · Phrachomklao Hospital · Prapokklao Hospital
+6 more
· Queen Sirikit National Institute of Child Health · Sappasitthiprasong Hospital · Srinagarind Hospital, Khon Kaen University · Surin Hospital · The HIV Netherlands Australia Thailand Research Collaboration · UdonThani Hospital

today NCT01307124 · Ph 3

20112012201320142015201620172018201920202021202220232024202520262027

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 3	NCT01307124	Mar 2011 → Apr 2013	congenital human immunodeficiency virus	The HIV Netherlands Australia Thailand Research Collaboration	Completed	No outcome recorded

Every value below carries the sentence it was read from. 1 source stands behind the page.

Field	Value	Cited text
Known as	Lopinavir/ritonavir	“The study participants will receive Lopinavir/ritonavir heat-stable tablet (100/25 mg or 200/50 mg) q 12 hour plus NRTIs.” NCT01307124 ↗